Cancer Control and Prevention Protocols
Leukemia, Myelodysplastic Syndrome
The National Myelodysplastic Syndromes (MDS) Study
Eligible for screening study DCP 001
This protocol has additional regulatory requirements to be completed prior to registering any patients at your site. Please contact Amber Boerner at 406-969-6067 or email@example.com for additional information.
To help protect the safety and welfare of human subject participants and research staff during the COVID-19 epidemic, enrollment of new participants on NHLBI-MDS is suspended effective immediately, 03/27/20, until further notice, and all follow-up research sample collection and shipment should be discontinued.